Antagonism of CRF2 receptors produces anxiolytic behavior in animal models of anxiety

被引:116
作者
Takahashi, LK
Ho, SP
Livanov, V
Graciani, N
Arneric, SP
机构
[1] Univ Hawaii, Dept Psychol, Honolulu, HI 96822 USA
[2] Dupont Merck Pharmaceut Co, CNS Dis Res, Wilmington, DE 19880 USA
关键词
corticotropin-releasing factor (CRF) receptor; anxiety; CRF2; antagonist; anxiolytic behavior; animal anxiety model; stress;
D O I
10.1016/S0006-8993(01)02405-2
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Two pharmacologically distinct CRF receptors are distributed in different brain regions and peripheral tissues. Studies suggest that CRF, receptors play an important role in mediating the anxiety provoking effects of CRF. In contrast, far less functional information is available on CRF, receptors. Therefore, we conducted dose response studies using antisauvagine-30 (anti-SVG-30, 0-20 mug, 20-min pretreatment, i.c.v.), a potent CRF2 peptide antagonist, and tested rats in three models of anxiety - the conditioned freezing, the elevated plus maze, and the defensive-withdrawal test. Anti-SVG-30 produced a significant dose-dependent reduction in conditioned freezing. In the elevated plus maze test, administration of anti-SVG-30 effectively increased the number of entries and time spent in the open arms. In the defensive-withdrawal test, anti-SVG-30 treatment facilitated exploratory activity in a large illuminated open field. Thus, in all three animal models, administration of anti-SVG-30 was consistent in producing an anxiolytic like behavioral effect. In addition, a dose of anti-SVG-30 (10 mug) that produced anxiolytic-like behavior had no significant effects on locomotor activity measured in an automated activity box. This latter finding suggests that antagonism of CRF, receptors is not associated with a non-specific increase in behavioral movements. These results provide evidence that, in addition to CRF, receptors, CRF, receptors may play an important role in the mediation of anxiety behavior. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:135 / 142
页数:8
相关论文
共 53 条
[11]  
DEBELLIS MD, 1993, AM J PSYCHIAT, V150, P656
[12]   Corticotropin-releasing factor receptors: Physiology, pharmacology, biochemistry and role in central nervous system and immune disorders [J].
DeSouza, EB .
PSYCHONEUROENDOCRINOLOGY, 1995, 20 (08) :789-819
[13]   LOW-DOSES OF MUSCIMOL PRODUCE ANTICONFLICT ACTIONS IN THE LATERAL SEPTUM OF THE RAT [J].
DRUGAN, RC ;
SKOLNICK, P ;
PAUL, SM ;
CRAWLEY, JN .
NEUROPHARMACOLOGY, 1986, 25 (02) :203-205
[14]   Neuroanatomical characterization of Fos induction in rat behavioral models of anxiety [J].
Duncan, GE ;
Knapp, DJ ;
Breese, GR .
BRAIN RESEARCH, 1996, 713 (1-2) :79-91
[15]   PHYSIOLOGICAL AND BEHAVIORAL-RESPONSES TO CORTICOTROPIN-RELEASING FACTOR ADMINISTRATION - IS CRF A MEDIATOR OF ANXIETY OR STRESS RESPONSES [J].
DUNN, AJ ;
BERRIDGE, CW .
BRAIN RESEARCH REVIEWS, 1990, 15 (02) :71-100
[16]   The discovery of 4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-α]-pyrimidine:: A corticotropin-releasing factor (hCRF1) antagonist [J].
Gilligan, PJ ;
Baldauf, C ;
Cocuzza, A ;
Chidester, D ;
Zaczek, R ;
Fitzgerald, LW ;
McElroy, J ;
Smith, MA ;
Shen, HSL ;
Saye, JA ;
Christ, D ;
Trainor, G ;
Robertson, DW ;
Hartig, P .
BIOORGANIC & MEDICINAL CHEMISTRY, 2000, 8 (01) :181-189
[17]   Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders? [J].
Griebel, G .
PHARMACOLOGY & THERAPEUTICS, 1999, 82 (01) :1-61
[18]  
Griebel G, 1998, PSYCHOPHARMACOLOGY, V138, P55
[19]   Corticotropin-releasing factor CRF1, but not CRF2, receptors mediate anxiogenic-like behavior [J].
Heinrichs, SC ;
Lapsansky, J ;
Lovenberg, TW ;
DeSouza, EB ;
Chalmers, DT .
REGULATORY PEPTIDES, 1997, 71 (01) :15-21
[20]   125I-antisauvagine-30:: a novel and specific high-affinity radioligand for the characterization of corticotropin-releasing factor type 2 receptors [J].
Higelin, J ;
Py-Lang, G ;
Paternoster, C ;
Ellis, GJ ;
Patel, A ;
Dautzenberg, FM .
NEUROPHARMACOLOGY, 2001, 40 (01) :114-122